Literature DB >> 33646017

Sodium Fluoride-18 and Radium-223 Dichloride Uptake Colocalize in Osteoblastic Mouse Xenograft Tumors.

Tim E Phelps1, Jyoti Roy1, Michael V Green1,2, Jurgen Seidel1,2, Kwamena E Baidoo1, Stephen Adler2, Elijah F Edmondson3, Donna Butcher3, Jennifer L Matta3, Anita T Ton1, Karen Wong1, Shan Huang1, Ling Ren1, Amy K LeBlanc1, Peter L Choyke1, Elaine M Jagoda1.   

Abstract

Background: Patients with osteoblastic bone metastases are candidates for radium-223 (223RaCl2) therapy and may undergo sodium fluoride-18 (18F-NaF) positron emission tomography-computed tomography imaging to identify bone lesions. 18F-NaF has been shown to predict 223RaCl2 uptake, but intratumor distributions of these two agents remain unclear. In this study, the authors evaluate the spatial distribution and relative uptakes of 18F-NaF and 223RaCl2 in Hu09-H3 human osteosarcoma mouse xenograft tumors at macroscopic and microscopic levels to better quantify their correlation. Materials and
Methods: 18F-NaF and 223RaCl2 were co-injected into Hu09-H3 xenograft tumor severe combined immunodeficient mice. Tumor content was determined from in vivo biodistributions and visualized by PET, single photon emission computed tomography, and CT imaging. Intratumor distributions were visualized by quantitative autoradiography of tumor tissue sections and compared to histology of the same or adjacent sections.
Results: 18F and 223Ra accumulated in proportional amounts in whole Hu09-H3 tumors (r2 = 0.82) and in microcalcified regions within these tumors (r2 = 0.87). Intratumor distributions of 18F and 223Ra were spatially congruent in these microcalcified regions. Conclusions: 18F-NaF and 223RaCl2 uptake are strongly correlated in heterogeneously distributed microcalcified regions of Hu09-H3 xenograft tumors, and thus, tumor accumulation of 18F is predictive of 223Ra accumulation. Hu09-H3 xenograft tumors appear to possess certain histopathological features found in patients with metastatic bone disease and may be useful in clarifying the relationship between administered 223Ra dose and therapeutic effect.

Entities:  

Keywords:  bone lesions; fluoride-18; imaging; metastatic cancer; microcalcifications; radium-223

Mesh:

Substances:

Year:  2021        PMID: 33646017      PMCID: PMC7994428          DOI: 10.1089/cbr.2020.4068

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  51 in total

Review 1.  Molecular mechanisms of bone 18F-NaF deposition.

Authors:  Johannes Czernin; Nagichettiar Satyamurthy; Christiaan Schiepers
Journal:  J Nucl Med       Date:  2010-11-15       Impact factor: 10.057

2.  Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.

Authors:  Elba C Etchebehere; John C Araujo; Patricia S Fox; Nancy M Swanston; Homer A Macapinlac; Eric M Rohren
Journal:  J Nucl Med       Date:  2015-06-11       Impact factor: 10.057

3.  Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group.

Authors:  Joe M O'Sullivan; Joan Carles; Richard Cathomas; Alfonso Gomez-Iturriaga; Daniel Heinrich; Gero Kramer; Piet Ost; Inge van Oort; Bertrand Tombal
Journal:  Eur Urol Oncol       Date:  2019-03-26

4.  The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.

Authors:  Einat Even-Sapir; Ur Metser; Eyal Mishani; Gennady Lievshitz; Hedva Lerman; Ilan Leibovitch
Journal:  J Nucl Med       Date:  2006-02       Impact factor: 10.057

5.  Alpha emitter radium-223 and survival in metastatic prostate cancer.

Authors:  C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

6.  Distribution of metastatic sites in patients with prostate cancer: A population-based analysis.

Authors:  Giorgio Gandaglia; Firas Abdollah; Jonas Schiffmann; Vincent Trudeau; Shahrokh F Shariat; Simon P Kim; Paul Perrotte; Francesco Montorsi; Alberto Briganti; Quoc-Dien Trinh; Pierre I Karakiewicz; Maxine Sun
Journal:  Prostate       Date:  2013-10-16       Impact factor: 4.104

7.  Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.

Authors:  Oliver Sartor; Robert Coleman; Sten Nilsson; Daniel Heinrich; Svein I Helle; Joe M O'Sullivan; Sophie D Fosså; Aleš Chodacki; Paweł Wiechno; John Logue; Anders Widmark; Dag Clement Johannessen; Peter Hoskin; Nicholas D James; Arne Solberg; Isabel Syndikus; Nicholas J Vogelzang; C Gillies O'Bryan-Tear; Minghua Shan; Øyvind S Bruland; Christopher Parker
Journal:  Lancet Oncol       Date:  2014-05-13       Impact factor: 41.316

8.  QuPath: Open source software for digital pathology image analysis.

Authors:  Peter Bankhead; Maurice B Loughrey; José A Fernández; Yvonne Dombrowski; Darragh G McArt; Philip D Dunne; Stephen McQuaid; Ronan T Gray; Liam J Murray; Helen G Coleman; Jacqueline A James; Manuel Salto-Tellez; Peter W Hamilton
Journal:  Sci Rep       Date:  2017-12-04       Impact factor: 4.379

Review 9.  Bone regeneration: molecular and cellular interactions with calcium phosphate ceramics.

Authors:  Florence Barrère; Clemens A van Blitterswijk; Klaas de Groot
Journal:  Int J Nanomedicine       Date:  2006

10.  Is interim 18F-fluoride PET/CT a predictor of outcomes after radium-223 therapy?

Authors:  Elba Etchebehere; Ana Emília Brito; Kalevi Kairemo; Eric Rohren; John Araujo; Homer Macapinlac
Journal:  Radiol Bras       Date:  2019 Jan-Feb
View more
  1 in total

1.  Why bother with alpha particles?

Authors:  A Paden King; Frank I Lin; Freddy E Escorcia
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-27       Impact factor: 9.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.